Literature DB >> 27021327

dfrA thyA Double Deletion in para-Aminosalicylic Acid-Resistant Mycobacterium tuberculosis Beijing Strains.

Danesh Moradigaravand1, Louis Grandjean2, Elena Martinez3, Hao Li4, Jun Zheng5, Jorge Coronel6, David Moore7, M Estée Török8, Vitali Sintchenko3, Hairong Huang9, Babak Javid10, Julian Parkhill1, Sharon J Peacock11, Claudio U Köser12.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27021327      PMCID: PMC4879365          DOI: 10.1128/AAC.00253-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


× No keyword cloud information.

LETTER

para-Aminosalicylic acid (PAS) is a group 4 antituberculosis agent (1). It targets folate metabolism as shown in Fig. S1 in the supplemental material, which also summarizes the known mechanisms of resistance to this prodrug (2). Recently, we reported a multidrug-resistant (MDR) Mycobacterium tuberculosis Beijing strain harboring a deletion of both dfrA and thyA from Australia (Fig. 1A and Table S1) (3). Since then, we have found deletions affecting both genes in five further MDR Beijing strains (two isolated in Australia and three from Peru) and one extensively drug-resistant (XDR) Beijing strain from China. The Australian MDR strains were recovered from three patients with no apparent epidemiological links who were likely infected in their country of origin (Table S1). The three Peruvian isolates were closely related and consequently shared the same deletion, whereas the remaining strains were distantly related and had deletions that differed in size (Fig. 1A). Consequently, these five distinct deletions were acquired independently, which can be a signal for positive selection of resistance mechanisms. In line with this hypothesis, the strains from Australia and China were found to be PAS resistant when tested with the Bactec MGIT 960 system and on Löwenstein-Jensen medium, respectively (see Supplemental methods). Two out of the three Peruvian deletion mutants were also found to be PAS resistant on 7H10 medium at 8 μg/ml, whereas the two closely related ancestral wild-type strains were found to be susceptible (Fig. 1B). We were unable to retest the strains at 2 μg/ml, the critical concentration recommended by the Clinical and Laboratory Standards Institute and the World Health Organization, which would have clarified whether the result for the third deletion mutant as susceptible was an artifact (1, 4).
FIG 1

Analysis of dfrA and thyA deletion strains, all of which tested PAS resistant, with the exception of PH107_CA033M_1. (A) Diagram of deletions in seven clinical strains compared with the wild-type H37Rv laboratory strain. The scale at the top corresponds to the genome position in H37Rv. The letter in parentheses denotes the country of isolation (Australia [A], China [C], and Peru [P]). Mtb97 was reported previously (3). (B) Maximum likelihood tree based on whole-genome data of the three Peruvian deletion mutants, which also share a mutation upstream of thyX that is also present in Mtb97 and Mtb78 (Table S1), and two closely related wild-type strains, which were PAS susceptible.

Analysis of dfrA and thyA deletion strains, all of which tested PAS resistant, with the exception of PH107_CA033M_1. (A) Diagram of deletions in seven clinical strains compared with the wild-type H37Rv laboratory strain. The scale at the top corresponds to the genome position in H37Rv. The letter in parentheses denotes the country of isolation (Australia [A], China [C], and Peru [P]). Mtb97 was reported previously (3). (B) Maximum likelihood tree based on whole-genome data of the three Peruvian deletion mutants, which also share a mutation upstream of thyX that is also present in Mtb97 and Mtb78 (Table S1), and two closely related wild-type strains, which were PAS susceptible. The observation that dfrA could be deleted was remarkable in light of our current understanding of folate metabolism in M. tuberculosis. Two studies suggested that dfrA is essential in vitro in the H37Rv laboratory strain (5, 6). More recently, it was shown that dfrA is conditionally essential and can be knocked out in H37Rv only if Rv2671 is overexpressed in trans, presumably due to its greatly reduced dihydrofolate reductase activity compared to that of DfrA (7, 8). Our in silico analysis of the seven dfrA thyA double deletion mutants did not reveal any known Rv2671 mutations (Table S1), such as the G-to-A upstream mutation at position −12 that results in its overexpression and consequently confers PAS resistance (this mutation was incorrectly referred to as affecting position −11 in two of our prior studies [7, 9]). Assuming that no other pertinent differences that are specific to the Beijing genotype relative to H37Rv exist or that a yet-unknown acquired mutation elsewhere in the genome that resulted in the overexpression of Rv2671 was present, we propose that this apparent contradiction can be reconciled if the essentiality of dfrA was dependent not only on the expression level of Rv2671 but also on the presence of wild-type thyA. The fact that thyA was deleted in all seven dfrA mutants meant that only the second thymidylate synthase, encoded by the essential thyX gene, was active in these strains (Fig. S1). Contrary to ThyA, ThyX generates tetrahydrofolate rather than dihydrofolate upon catalysis and therefore does not require high dihydrofolate reductase activity to provide sufficient levels of tetrahydrofolate (2). This is in line with the fact that dfrA is not required in bacterial species that lack thyA (10). Consequently, Rv2671 appeared to be sufficient to sustain growth, even without being overexpressed in these deletion mutants. It should therefore be possible to knock out dfrA in strains of M. tuberculosis with inactive thyA. Moreover, the adjacent locations of thyA and dfrA in the genome should make their simultaneous deletion possible (Fig. 1A). Interestingly, all but one of the deletion mutants also convergently acquired mutations upstream of thyX compared to what was observed for the two closely related Peruvian control strains (Fig. 1B and Table S1) (11). In fact, the cluster of three Peruvian strains and two of the unrelated Australian strains shared the same C-to-T upstream mutation at position −16 that has previously been found to be associated with resistance to several drugs and experimentally shown to result in the overexpression of thyX (12). It is therefore plausible that these changes compensated for the reduced expression levels and enzymatic activity of ThyX compared to those of ThyA (11, 13). Based on our data, however, it was not possible to deduce whether the thyX mutations were acquired after the deletions of thyA and dfrA in each strain, as would be expected with compensatory mutations (11). In summary, these data demonstrated that the folate metabolism and the genetic basis of PAS resistance are more complex than previously appreciated, which is relevant for the development of novel DfrA and ThyX inhibitors and potentially the use of trimethoprim-sulfamethoxazole to treat drug-resistant tuberculosis (Fig. S1) (14–25). Although deletions are often excluded from large-scale whole-genome studies, owing to the limited read lengths of next-generation sequencers and the fact that algorithms are optimized for single-nucleotide polymorphism (SNP) calling, this study highlighted that deletions can no longer be ignored (3, 26).
  24 in total

1.  Life without dihydrofolate reductase FolA.

Authors:  Hannu Myllykallio; Damien Leduc; Jonathan Filee; Ursula Liebl
Journal:  Trends Microbiol       Date:  2003-05       Impact factor: 17.079

2.  Synthesis and evaluation of C-5 modified 2'-deoxyuridine monophosphates as inhibitors of M. tuberculosis thymidylate synthase.

Authors:  Liudmila A Alexandrova; Vladimir O Chekhov; Eduard R Shmalenyuk; Sergey N Kochetkov; Rania Abu El-Asrar; Piet Herdewijn
Journal:  Bioorg Med Chem       Date:  2015-10-09       Impact factor: 3.641

3.  Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance.

Authors:  Hongtai Zhang; Dongfang Li; Lili Zhao; Joy Fleming; Nan Lin; Ting Wang; Zhangyi Liu; Chuanyou Li; Nicholas Galwey; Jiaoyu Deng; Ying Zhou; Yuanfang Zhu; Yunrong Gao; Tong Wang; Shihua Wang; Yufen Huang; Ming Wang; Qiu Zhong; Lin Zhou; Tao Chen; Jie Zhou; Ruifu Yang; Guofeng Zhu; Haiying Hang; Jia Zhang; Fabin Li; Kanglin Wan; Jun Wang; Xian-En Zhang; Lijun Bi
Journal:  Nat Genet       Date:  2013-09-01       Impact factor: 38.330

4.  Antifolate Activity of Plant Polyphenols against Mycobacterium tuberculosis.

Authors:  Archana Raju; Mariam S Degani; Mihir P Khambete; M K Ray; M G R Rajan
Journal:  Phytother Res       Date:  2015-08-15       Impact factor: 5.878

5.  Synthesis and evaluation of 6-aza-2'-deoxyuridine monophosphate analogs as inhibitors of thymidylate synthases, and as substrates or inhibitors of thymidine monophosphate kinase in Mycobacterium tuberculosis.

Authors:  Martin Kögler; Roger Busson; Steven De Jonghe; Jef Rozenski; Kristien Van Belle; Thierry Louat; Hélène Munier-Lehmann; Piet Herdewijn
Journal:  Chem Biodivers       Date:  2012-03       Impact factor: 2.408

Review 6.  Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance.

Authors:  Yusuke Minato; Joshua M Thiede; Shannon Lynn Kordus; Edward J McKlveen; Breanna J Turman; Anthony D Baughn
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

7.  Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012.

Authors:  Xiaobing Zhang; Liguo Liu; Yan Zhang; Guangming Dai; Hairong Huang; Qi Jin
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

8.  Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis.

Authors:  Diana Machado; Isabel Couto; João Perdigão; Liliana Rodrigues; Isabel Portugal; Pedro Baptista; Bruno Veigas; Leonard Amaral; Miguel Viveiros
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

9.  High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity.

Authors:  Anuradha Kumar; Meng Zhang; Linyun Zhu; Reiling P Liao; Charles Mutai; Shittu Hafsat; David R Sherman; Ming-Wei Wang
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

10.  ProTides of N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents.

Authors:  Christopher McGuigan; Marco Derudas; Blanka Gonczy; Karen Hinsinger; Sahar Kandil; Fabrizio Pertusati; Michaela Serpi; Robert Snoeck; Graciela Andrei; Jan Balzarini; Timothy D McHugh; Arundhati Maitra; Ernest Akorli; Dimitrios Evangelopoulos; Sanjib Bhakta
Journal:  Bioorg Med Chem       Date:  2014-03-15       Impact factor: 3.641

View more
  9 in total

1.  Drugging the Folate Pathway in Mycobacterium tuberculosis: The Role of Multi-targeting Agents.

Authors:  Behnoush Hajian; Eric Scocchera; Carolyn Shoen; Jolanta Krucinska; Kishore Viswanathan; Narendran G-Dayanandan; Heidi Erlandsen; Alexavier Estrada; Katarína Mikušová; Jana Korduláková; Michael Cynamon; Dennis Wright
Journal:  Cell Chem Biol       Date:  2019-03-28       Impact factor: 8.116

2.  Deletion of sigB Causes Increased Sensitivity to para-Aminosalicylic Acid and Sulfamethoxazole in Mycobacterium tuberculosis.

Authors:  Shan-Shan Yang; Yang-Bo Hu; Xu-De Wang; Yun-Rong Gao; Kun Li; Xian-En Zhang; Shi-Yun Chen; Tian-Yu Zhang; Jing Gu; Jiao-Yu Deng
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 3.  Revitalizing antifolates through understanding mechanisms that govern susceptibility and resistance.

Authors:  Shannon Lynn Kordus; Anthony David Baughn
Journal:  Medchemcomm       Date:  2019-05-08       Impact factor: 3.597

4.  The variability and reproducibility of whole genome sequencing technology for detecting resistance to anti-tuberculous drugs.

Authors:  Jody Phelan; Denise M O'Sullivan; Diana Machado; Jorge Ramos; Alexandra S Whale; Justin O'Grady; Keertan Dheda; Susana Campino; Ruth McNerney; Miguel Viveiros; Jim F Huggett; Taane G Clark
Journal:  Genome Med       Date:  2016-12-22       Impact factor: 11.117

5.  A biochemically-interpretable machine learning classifier for microbial GWAS.

Authors:  Erol S Kavvas; Laurence Yang; Jonathan M Monk; David Heckmann; Bernhard O Palsson
Journal:  Nat Commun       Date:  2020-05-22       Impact factor: 14.919

6.  Whole genome sequencing reveals large deletions and other loss of function mutations in Mycobacterium tuberculosis drug resistance genes.

Authors:  Laura C Gomes; Susana Campino; Cláudio R F Marinho; Taane G Clark; Jody E Phelan
Journal:  Microb Genom       Date:  2021-12

7.  Machine learning and structural analysis of Mycobacterium tuberculosis pan-genome identifies genetic signatures of antibiotic resistance.

Authors:  Erol S Kavvas; Edward Catoiu; Nathan Mih; James T Yurkovich; Yara Seif; Nicholas Dillon; David Heckmann; Amitesh Anand; Laurence Yang; Victor Nizet; Jonathan M Monk; Bernhard O Palsson
Journal:  Nat Commun       Date:  2018-10-17       Impact factor: 14.919

8.  Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase.

Authors:  Matthew Ezewudo; Amanda Borens; Álvaro Chiner-Oms; Paolo Miotto; Leonid Chindelevitch; Angela M Starks; Debra Hanna; Richard Liwski; Matteo Zignol; Christopher Gilpin; Stefan Niemann; Thomas Andreas Kohl; Robin M Warren; Derrick Crook; Sebastien Gagneux; Sven Hoffner; Camilla Rodrigues; Iñaki Comas; David M Engelthaler; David Alland; Leen Rigouts; Christoph Lange; Keertan Dheda; Rumina Hasan; Ruth McNerney; Daniela M Cirillo; Marco Schito; Timothy C Rodwell; James Posey
Journal:  Sci Rep       Date:  2018-10-18       Impact factor: 4.379

9.  PARMAP: A Pan-Genome-Based Computational Framework for Predicting Antimicrobial Resistance.

Authors:  Xuefei Li; Jingxia Lin; Yongfei Hu; Jiajian Zhou
Journal:  Front Microbiol       Date:  2020-10-22       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.